Back to Search
Start Over
Multimodal detection of molecular residual disease in high-risk locally advanced squamous cell carcinoma of the head and neck.
- Source :
-
Cell death and differentiation [Cell Death Differ] 2024 Apr; Vol. 31 (4), pp. 460-468. Date of Electronic Publication: 2024 Feb 26. - Publication Year :
- 2024
-
Abstract
- Up to 30% of patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) relapse. Molecular residual disease (MRD) detection using multiple assays after definitive therapy has not been reported. In this study, we included patients with LA-HNSCC (stage III Human Papilloma virus (HPV)-positive, III-IVB HPV-negative) treated with curative intent. Plasma was collected pre-treatment, at 4-6 weeks (FU1) and 8-12 weeks (FU2) post-treatment. Circulating tumor DNA (ctDNA) was analyzed using a tumor-informed (RaDaR®) and a tumor-naïve (CAPP-seq) assay. HPV DNA was measured using HPV-sequencing (HPV-seq) and digital PCR (dPCR). A total of 86 plasma samples from 32 patients were analyzed; all patients with at least 1 follow-up sample. Most patients were stage III HPV-positive (50%) and received chemoradiation (78%). No patients had radiological residual disease at FU2. With a median follow-up of 25 months, there were 7 clinical relapses. ctDNA at baseline was detected in 15/17 (88%) by RaDaR and was not associated with recurrence free survival (RFS). Two patients relapsed within a year after definitive therapy and showed MRD at FU2 using RaDaR; detection of ctDNA during follow-up was associated with shorter RFS (p < 0.001). ctDNA detection by CAPP-seq pre-treatment and during follow-up was not associated with RFS (p = 0.09). HPV DNA using HPV-seq or dPCR during follow-up was associated with shorter RFS (p < 0.001). Sensitivity and specificity for MRD at FU2 using RaDaR was 40% and 100% versus 20 and 90.5% using CAPP-seq. Sensitivity and specificity for MRD during follow-up using HPV-seq was 100% and 91.7% versus 50% and 100% using dPCR. In conclusion, HPV DNA and ctDNA can be detected in LA-HNSCC before definitive therapy. The RaDaR assay but not CAPP-seq may detect MRD in patients who relapse within 1 year. HPV-seq may be more sensitive than dPCR for MRD detection.<br /> (© 2024. The Author(s).)
- Subjects :
- Humans
Male
Female
Middle Aged
Aged
Adult
Circulating Tumor DNA genetics
Circulating Tumor DNA blood
DNA, Viral genetics
Neoplasm Recurrence, Local
Aged, 80 and over
Neoplasm, Residual
Squamous Cell Carcinoma of Head and Neck genetics
Squamous Cell Carcinoma of Head and Neck virology
Squamous Cell Carcinoma of Head and Neck pathology
Head and Neck Neoplasms pathology
Head and Neck Neoplasms genetics
Head and Neck Neoplasms diagnosis
Head and Neck Neoplasms virology
Subjects
Details
- Language :
- English
- ISSN :
- 1476-5403
- Volume :
- 31
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Cell death and differentiation
- Publication Type :
- Academic Journal
- Accession number :
- 38409276
- Full Text :
- https://doi.org/10.1038/s41418-024-01272-y